Uppsala, Sweden, July 20, 2015 – CIS Pharma has submitted to the Swedish competent authority MPA the marketing authorization application for intracameral cefuroxime. The decentralized procedure is led by Sweden as reference member states with a total of seventeen reference member states across Europe. The CIS Pharma team is proud to have achieved the first major milestone in the agreement with its licensee and to potentially save thousands of patients from going blind. CIS Pharma’s licensee has a strong market penetration and is expected to grant a fast adoption of the procedure throughout Europe.
About CIS Pharma’s cefuroxime application system
The cefuroxime application system is CIS Pharma’s patented drug/device combination for preparation and injection of cefuroxime intracameral antibiotic to prevent Endophthalmitis after cataract surgery. It meets the cataract surgeon’s need to dilute and inject 1mg cefuroxime in a safe, precise and standardized manner. Every year, 20 million cataract patients receive an intraocular lens. Endophthalmitis, also called intravitreal infection, is a rare but severe inflammatory condition of the eye, caused by microbial contamination during the surgical procedure. Cefuroxime intracameral prophylaxis was found to reduce the risk of Endophthalmitis by a factor 5, whereas topical antibiotics have no effect on the outcome.
About CIS Pharma AG
CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of therapeutics that are the standard of care, thereby improving patient’s experience and treatment outcome. Medical need, patient centricity and digital technology are key to our research and development programs. CIS Pharma is located in the region of Basel, Switzerland, one of the most successful life sciences locations in the world. For more information about the company, visit our website www.cis-pharma.com.